Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-04
2009-08-18
Tate, Christopher R. (Department: 1655)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S454000, C514S455000, C549S264000, C549S334000, C424S736000
Reexamination Certificate
active
07576123
ABSTRACT:
Compositions, methods, etc. for addressing the first-pass effect.
REFERENCES:
patent: 5061502 (1991-10-01), Cally et al.
patent: 5362714 (1994-11-01), Radford et al.
patent: 5820915 (1998-10-01), Harris
patent: 5962044 (1999-10-01), Harris
patent: 5990154 (1999-11-01), Harris
patent: 5993887 (1999-11-01), Harris
patent: 6054477 (2000-04-01), Harris
patent: 6063809 (2000-05-01), Harris
patent: 6124477 (2000-09-01), Harris
patent: 6162479 (2000-12-01), Harris
patent: 6248776 (2001-06-01), Harris
patent: 6255337 (2001-07-01), Harris
patent: 6309687 (2001-10-01), Harris
patent: 6476066 (2002-11-01), Harris
patent: 6613918 (2003-09-01), Seemayer et al.
patent: 6660766 (2003-12-01), Harris
patent: 7230027 (2007-06-01), Harris
patent: 2003/0235632 (2003-12-01), Harris
patent: 2004/0058982 (2004-03-01), Harris
patent: 2005/0171191 (2005-08-01), Harris
patent: 2007/0287664 (2007-12-01), Ralston et al.
patent: 1 084 733 (1958-08-01), None
patent: 57-179186 (1982-11-01), None
patent: 62-75450 (1987-04-01), None
patent: 62-80642 (1987-04-01), None
patent: 62-173456 (1987-07-01), None
patent: 62-173457 (1987-07-01), None
patent: 95/02589 (1995-01-01), None
patent: WO 98/07332 (1998-02-01), None
Ohta et al. Tetrahedron. 2002. vol. 58, pp. 6631-6635.
Guo et al. Drug Metabolism and Disposition. 2000. vol. 28, No. 7, pp. 766-771.
Teemu Kantola; Clinical Pharmacology & Therapeutics; “Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid”; vol. 63, No. 4; pp. 397-402; Apr. 1998.
Jari J. Lilja; Clinical Pharmacology & Therapeutics; “Grapefruit juice susbstantially increases plasma concentrations of buspirone”; vol. 64, No. 6; pp. 655-660; Dec. 1998.
Jari J. Lilja; Clinical Pharmacology & Therapeutics; “Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors”; vol. 64, No. 5; pp. 477-483: Nov. 1998.
Stephen Cross; Proc. Fla. State Hort. Soc. “Membrane Concentration of Orange Juice”; vol. 102, pp. 146-152, 1989.
Ernesto Hernandez; J. Agric. Food Chem. “Ultrafiltration of Orange Juice: Effect on Soluble Solids, Suspended Solids, and Aroma”; vol. 40, No. 6, pp. 986-988; 1992.
G. Capannelli; Lebensm-Wiss. U.-Technol. “Ultrafiltration of Fresh Orange and Lemon Juices”; vol. 25, No. 6, pp. 518-522; 1992.
J.R. Johnson; Journal of Food and Science; “Flavor Losses in Orange Juice during Ultrafiltration and Subsequent Evaporation”; vol. 61, No. 3, pp. 540-543; 1996.
E. Hernandez; Journal of Food and Science; “Evaluation of Ultrafiltration and Adsorption to Debitter Grapefruit Juice and Grapefruit Pulp Wash”; vol. 57, No. 3, pp. 664-670; 1992.
Search Request Letter; Jan. 22, 1999.
Search Results; Answers 1-12; Jan. 22, 1999.
Masahiko Taniguchi, et al.; “Rivulobirins C and D, Two Novel New Spirobicoumarins, From the Underground Part of Pleurospermum Rivulorum”; Chem. Pharm. Bull. 46(6) pp. 1065-1067; Jun. 1998.
C. Van Tamelen, E.E., et al.; “Biogenetic-Type Total Synthesis of (±) Farnesiferol A and (±)-Farnesiferol C”; Bioorganic Chemistry, vol. 11, pp. 171-196; 1982 (w/attached chemical abstract).
David J. Collins, et al.; “Enolic Ortho Esters. I Preparation and Birch Reduction of Some Coumarinoid Ortho Esters”; Aust. J. Chem., vol. 42, pp. 1235-1248; 1989.
Sato Kozo, et al.; “Studies on the synthesis of spiropyran derivatives. III. Reactions of coumarin diethyl acetal with nucleophiles”; (Fac. Eng., Tokyo Inst. Technol., Tokyo, Japan); Nippon Kagaku Kaishi, No. 3, pp. 492-496 (Japanese); 1976 (w/attached English Abstract).
Kurt Bodenbenner, et al.; “Bicyclic acetals”; Chemical Abstracts; vol. 55, pp. 20963.
Kurt Bodenbenner; “Spirocyclic ortho esters”; (Bayer Akt.-Ges., Leverkusen, Ger.), Ann. vol. 623, pp. 183-191; 1959 (w/English Abstract).
U.S. Appl. No. 11/747,256, filed May 11, 2007, Harris.
U.S. Appl. No. 11/696,198, filed Apr. 4, 2007, Harris.
Bioavailability Systems, L.L.C.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Tate Christopher R.
LandOfFree
Anti-first-pass effect compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-first-pass effect compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-first-pass effect compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113176